Fractyl Health, Inc. (GUTS)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Fractyl Health, Inc. (GUTS) trades at $0.81 with AI Score 24/100 (Grade F). Fractyl Health, Inc. is a metabolic therapeutics company focused on developing therapies for type 2 diabetes and obesity. Market cap: $58.68M, Sector: Healthcare.
Price live · AI analysis from May 9, 2026GUTS stock analysis for 2026: Analysts have set a consensus price target of $2.00 for Fractyl Health, Inc., suggesting 146.1% upside from the current price of $0.81. The AI MoonshotScore is 24/100, indicating a strong bearish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
GUTS: 1/1 perspectives are bearish.
How is this calculated? →Fractyl Health, Inc. (GUTS) Healthcare & Pipeline Overview
Fractyl Health, Inc. is a biotechnology company specializing in metabolic therapeutics, targeting type 2 diabetes and obesity. Its lead product, the Revita DMR System, aims to modify duodenal dysfunction through outpatient procedures. The company also develops gene therapy platforms for long-term disease remission, positioning it within the innovative metabolic disease treatment landscape.
What Is the Investment Thesis for GUTS?
Fractyl Health, Inc. presents a compelling investment thesis centered on its innovative approach to treating type 2 diabetes and obesity. The Revita DMR System offers a unique, minimally invasive procedural therapy targeting duodenal dysfunction, a key factor in metabolic disease progression. Successful clinical trials and regulatory approvals for Revita could drive significant revenue growth. The Rejuva gene therapy platform represents a longer-term growth opportunity, potentially providing a durable solution for metabolic diseases. However, the company faces risks associated with clinical trial outcomes, regulatory hurdles, and competition from established pharmaceutical companies. The company's market capitalization is $0.04 billion, and its beta is 1.19.
Based on FMP financials and quantitative analysis
GUTS Key Highlights
- Fractyl Health is focused on developing therapies for type 2 diabetes (T2D) and obesity, addressing a significant and growing global health challenge.
- The Revita DMR System is an outpatient procedural therapy designed to modify duodenal dysfunction, offering a novel approach to treating metabolic diseases.
- The company is developing Rejuva, a virus-delivered pancreatic gene therapy platform, with the potential to enable long-term remission of T2D and obesity.
- Fractyl Health, Inc. was founded in 2010 and is based in Lexington, Massachusetts.
- The company changed its name from Fractyl Laboratories Inc. to Fractyl Health, Inc. on June 09, 2021.
Who Are GUTS's Competitors?
GUTS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| LLY Eli Lilly and Company | $1202.56 | -0.94% | $1.13T | 98 |
| NVO Novo Nordisk A/S | $49.28 | -2.27% | $219.01B | 51 |
| ABBV AbbVie Inc. | $255.67 | -2.07% | $451.72B | 78 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are GUTS's Key Strengths?
- Innovative Revita DMR System targeting duodenal dysfunction.
- Novel Rejuva gene therapy platform with potential for long-term remission.
- Experienced management team with expertise in metabolic therapeutics.
- Strong intellectual property portfolio.
What Are GUTS's Weaknesses?
- Limited commercialization experience.
- Dependence on successful clinical trial outcomes and regulatory approvals.
- Relatively small company size compared to established pharmaceutical companies.
- High research and development costs.
What Could Drive GUTS Stock Higher?
- Clinical trial results for the Revita DMR System in new indications.
- Regulatory approvals for Revita in additional geographies.
- Development and advancement of the Rejuva gene therapy platform.
- Strategic partnerships and collaborations with other companies.
- Publication of clinical data supporting the efficacy and safety of Fractyl Health's therapies.
What Are the Key Risks for GUTS?
- Financial-distress signal — its Altman Z-Score of -10.26 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Unfavorable clinical trial results for Revita or Rejuva.
- Regulatory setbacks or delays in obtaining approvals.
- Competition from established pharmaceutical companies and other biotechnology firms.
- Changes in healthcare regulations and reimbursement policies.
- Economic downturn impacting healthcare spending and investment in biotechnology.
What Are the Growth Opportunities for GUTS?
- Expansion of Revita DMR System: Fractyl Health has the opportunity to expand the market reach of its Revita DMR System. This involves securing regulatory approvals in additional geographies, such as Europe and Asia, and increasing adoption among healthcare providers. The global market for diabetes treatment is projected to reach $160 billion by 2027, providing a substantial opportunity for Revita to capture a portion of this market. Successful commercialization and market penetration could significantly drive revenue growth for Fractyl Health.
- Development of Rejuva Gene Therapy Platform: The Rejuva gene therapy platform represents a significant long-term growth opportunity for Fractyl Health. Gene therapy for metabolic diseases is an emerging field with the potential to provide durable solutions. Successful development and clinical validation of Rejuva could position Fractyl Health as a leader in this space. The gene therapy market is projected to reach $25 billion by 2030, offering a substantial opportunity for Fractyl Health to capitalize on its Rejuva platform.
- Strategic Partnerships and Collaborations: Fractyl Health can pursue strategic partnerships and collaborations with pharmaceutical companies, medical device manufacturers, and research institutions to accelerate the development and commercialization of its therapies. Collaborations can provide access to additional resources, expertise, and funding, enhancing Fractyl Health's capabilities and market reach. These partnerships can also help to mitigate risks associated with clinical development and regulatory approvals.
- Expansion into Related Metabolic Diseases: Fractyl Health can leverage its expertise in metabolic therapeutics to expand into related disease areas, such as non-alcoholic steatohepatitis (NASH) and cardiovascular disease. These diseases share common metabolic pathways with type 2 diabetes and obesity, providing opportunities for Fractyl Health to develop new therapies and expand its market reach. The market for NASH treatments is projected to reach $20 billion by 2030, representing a significant growth opportunity.
- Data-Driven Personalized Medicine: Fractyl Health can leverage data analytics and artificial intelligence to personalize treatment approaches and improve patient outcomes. By collecting and analyzing patient data, the company can identify biomarkers and predictors of treatment response, allowing for more targeted and effective therapies. This data-driven approach can enhance the value proposition of Fractyl Health's therapies and attract patients seeking personalized medicine solutions.
What Opportunities Does GUTS Have?
- Expansion of Revita DMR System into new geographies.
- Development of new therapies for related metabolic diseases.
- Strategic partnerships and collaborations with other companies.
- Increasing prevalence of type 2 diabetes and obesity driving demand for new treatments.
What Threats Does GUTS Face?
- Competition from established pharmaceutical companies and other biotechnology firms.
- Unfavorable clinical trial results or regulatory setbacks.
- Changes in healthcare regulations and reimbursement policies.
- Economic downturn impacting healthcare spending.
What Are GUTS's Competitive Advantages?
- Proprietary Revita DMR System technology with patent protection.
- Novel Rejuva gene therapy platform targeting the root causes of metabolic diseases.
- First-mover advantage in developing duodenal modification therapies.
- Expertise in metabolic therapeutics and gene therapy development.
What Does GUTS Do?
Fractyl Health, Inc., established in 2010 and based in Lexington, Massachusetts, is a metabolic therapeutics company dedicated to developing innovative treatments for type 2 diabetes (T2D) and obesity. Originally known as Fractyl Laboratories Inc., the company rebranded in June 2021 to Fractyl Health, Inc., reflecting its expanded focus on metabolic health solutions. The company's primary product is the Revita DMR System (Revita), an outpatient procedural therapy designed to address duodenal dysfunction, a condition resulting from high-fat and high-sugar diets that can lead to T2D and obesity. Revita aims to durably modify this dysfunction, offering a novel approach to managing these metabolic diseases. In addition to Revita, Fractyl Health is developing Rejuva, a virus-delivered pancreatic gene therapy platform. Rejuva is designed to enable long-term remission of T2D and obesity by altering metabolic hormone function in the pancreatic islet cells. This innovative approach targets the root causes of metabolic dysfunction, potentially offering a more sustainable solution for patients. Fractyl Health's focus on both procedural and gene therapy approaches positions it as a key player in the evolving landscape of metabolic disease treatment.
What Products and Services Does GUTS Offer?
- Develops the Revita DMR System, an outpatient procedural therapy for type 2 diabetes and obesity.
- Targets duodenal dysfunction, a pathologic consequence of high-fat and high-sugar diets.
- Aims to durably modify duodenal dysfunction to improve metabolic health.
- Develops the Rejuva gene therapy platform for long-term remission of type 2 diabetes and obesity.
- Utilizes virus-delivered gene therapy to alter metabolic hormone function in pancreatic islet cells.
- Focuses on innovative approaches to treat the root causes of metabolic diseases.
How Does GUTS Make Money?
- Develops and commercializes medical devices and gene therapies for metabolic diseases.
- Generates revenue through sales of the Revita DMR System and future gene therapy products.
- Partners with healthcare providers and hospitals to offer Revita procedures.
- May pursue licensing agreements and collaborations with other companies.
What Industry Does GUTS Operate In?
Fractyl Health operates within the biotechnology industry, specifically focusing on metabolic therapeutics. The market for diabetes and obesity treatments is substantial and growing, driven by increasing prevalence rates globally. The competitive landscape includes established pharmaceutical companies developing drug therapies, as well as other biotechnology firms exploring novel approaches such as gene therapy and medical devices. Fractyl Health's Revita DMR System offers a unique approach compared to traditional drug therapies, potentially capturing a significant share of the market if proven effective and safe.
Who Are GUTS's Key Customers?
- Patients with type 2 diabetes and obesity.
- Healthcare providers and hospitals offering metabolic disease treatments.
- Payers, including insurance companies and government healthcare programs.
FY2026 estForward Outlook
Wall Street analysts project Fractyl Health, Inc. revenue of about $12.4M for fiscal 2026, with EPS near $-0.35. The estimate reflects 3 contributing analysts.
Key Financial Metrics
A current ratio of 4.28 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -179.3%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 2/9Financial Health
Fractyl Health, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -10.26 places it in the distress zone, a signal of elevated financial risk.
GUTS Valuation & Market Position
With a $58.68M market cap, Fractyl Health, Inc. sits in the micro-cap segment of the market. Relative to its peer group, GUTS's quantitative score of 24/100 is below the peer average of 77/100.
GUTS Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying indicates confidence in Fractyl's long-term prospects, suggesting that key stakeholders believe in the company's potential.
- Community sentiment has shifted positively, with discussions highlighting innovative treatments that Fractyl is developing, resonating well with investors.
- Recent partnerships and collaborations have been well-received, enhancing the company's credibility and market presence in the healthcare sector.
- Market perception has improved as Fractyl's pipeline shows promise, leading to increased interest from both retail and institutional investors.
Bear Case
- Concerns over regulatory hurdles have resurfaced, with some investors wary of the potential impact on timelines for product approvals.
- Community discussions reflect skepticism about the scalability of Fractyl's treatments, with some doubting their market adoption.
- Recent social sentiment has shown mixed feelings, with a segment of investors expressing doubts about the company's financial sustainability in the long term.
- Insider selling activity has raised red flags for some, leading to questions about the company's leadership confidence and future direction.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
GUTS Latest News
-
12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga · May 13, 2026
-
Earnings Scheduled For May 12, 2026
benzinga · May 12, 2026
-
Earnings Scheduled For August 12, 2025
benzinga · Aug 12, 2025
GUTS Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for GUTS.
Price Targets
Consensus target: $2.00
GUTS MoonshotScore
What does this score mean?
The MoonshotScore rates GUTS's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Harith Rajagopalan
CEO
Harith Rajagopalan serves as the Chief Executive Officer of Fractyl Health, Inc. His background includes extensive experience in the medical device and biotechnology industries. He has held leadership positions in various companies, focusing on strategic planning, product development, and commercialization. Rajagopalan's expertise spans across multiple therapeutic areas, including metabolic diseases, cardiovascular disease, and oncology. He holds advanced degrees in engineering and business administration, providing him with a strong foundation in both technical and business aspects of the healthcare industry.
Track Record: Under Harith Rajagopalan's leadership, Fractyl Health has focused on advancing the Revita DMR System and developing the Rejuva gene therapy platform. Key milestones include securing regulatory approvals for Revita in select markets and initiating clinical trials for Rejuva. Rajagopalan has also overseen strategic partnerships and collaborations to expand the company's reach and capabilities. His leadership has been instrumental in positioning Fractyl Health as an innovator in the metabolic therapeutics space.
What Investors Ask About Fractyl Health, Inc. (GUTS) — Healthcare
What does Fractyl Health, Inc. Common Stock do?
Fractyl Health, Inc. is a metabolic therapeutics company focused on developing and commercializing innovative treatments for type 2 diabetes and obesity. Its lead product, the Revita DMR System, is an outpatient procedural therapy designed to modify duodenal dysfunction, a key factor in metabolic disease progression. The company is also developing the Rejuva gene therapy platform, which aims to provide long-term remission of these diseases by altering metabolic hormone function in pancreatic islet cells. Fractyl Health's therapies offer novel approaches to addressing the root causes of metabolic dysfunction.
What do analysts say about GUTS stock?
Analyst coverage of Fractyl Health, Inc. is limited, given its market capitalization of $58.68M. Key valuation metrics and growth considerations are closely tied to the clinical trial outcomes and regulatory approvals for the Revita DMR System and the Rejuva gene therapy platform. Successful clinical trials and regulatory approvals could drive significant upside potential. However, the company faces risks associated with clinical development, regulatory hurdles, and competition. Investors should carefully consider these factors when evaluating GUTS stock.
What are the main risks for GUTS?
The main risks for Fractyl Health, Inc. include the potential for unfavorable clinical trial results for the Revita DMR System and the Rejuva gene therapy platform. Regulatory setbacks or delays in obtaining approvals could also significantly impact the company's prospects. Competition from established pharmaceutical companies and other biotechnology firms poses a challenge. Changes in healthcare regulations and reimbursement policies could affect the adoption of Fractyl Health's therapies. An economic downturn could impact healthcare spending and investment in biotechnology, affecting the company's ability to raise capital and fund its operations.
What are the key factors to evaluate for GUTS?
Fractyl Health, Inc. (GUTS) holds an AI score of 24/100 (low). Analysts target $2.00 (+146%). Not financial advice.
How frequently does GUTS data refresh on this page?
GUTS prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven GUTS's recent stock price performance?
Fractyl Health, Inc. (GUTS) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative Revita DMR System targeting duodenal dysfunction. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider GUTS overvalued or undervalued right now?
Valuing Fractyl Health, Inc. (GUTS) requires multiple metrics. Analysts target $2.00 (+146%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying GUTS?
Before investing in Fractyl Health, Inc. (GUTS), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Investment decisions should be based on thorough research and consultation with a financial advisor.